TICKERNERD
Menu
CORTCORTHealthcare · Biotechnology

CORT Stock Forecast: Corcept Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 6 Oct 2026
$120
−2.02% on the day

The 5 Wall Street analysts covering Corcept Therapeutics, Inc. hold a median 12-month price target of $164 — +37.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 5 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$12.9B
Ticker Nerd rank
79 / 100
Median analyst target
$164
Analysts covering
5
Revenue$256.1M+31.7% y/y
Operating income$41.3M
Net income$43.0M
Free cash flow$31.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.2%
1M
+7.1%
YTD
+243.6%
1Y
+33.1%
From 52W high
−3.2%
From 52W low
+271.9%
$32
$124
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CORT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Corcept Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 5 Oct 2026
79 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
95
Revisions
91
Quality
84
Momentum
78
Volatility
53
Growth
49
Accruals
42
Issuance
42
Size
13

Value (95): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (42): The company has been issuing shares or taking on financing, diluting existing holders.

Size (13): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CORT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CORT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150Jan 26Apr 26Jul 26Oct 26CORTHigh $165Median $164Low $50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
4 Buy0 Hold1 Sell
Low $50Median $164High $165

The green dot is the last close — the median target sits +37.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
18 Sept 2026HC Wainwright & Co.ReiteratesBuy$165
30 July 2026Canaccord GenuityMaintainsBuy—
30 July 2026Canaccord GenuityMaintainsBuy$150 → $161
30 July 2026HC Wainwright & Co.MaintainsBuy—
30 July 2026HC Wainwright & Co.MaintainsBuy$95 → $165
30 July 2026Piper SandlerReiteratesOverweight$88 → $165
30 July 2026Piper SandlerReiteratesOverweight—
29 July 2026Canaccord GenuityMaintainsBuy$135 → $150
29 July 2026Canaccord GenuityMaintainsBuy—
27 July 2026Wolfe ResearchDowngradeUnderperform—
27 July 2026Wolfe ResearchDowngradeUnderperform$50
28 May 2026Canaccord GenuityMaintainsBuy—
28 May 2026Canaccord GenuityMaintainsBuy$110 → $135
28 May 2026HC Wainwright & Co.MaintainsBuy—
28 May 2026HC Wainwright & Co.MaintainsBuy$75 → $95
13 May 2026UBSUpgradeBuy—
4 May 2026HC Wainwright & Co.MaintainsBuy—
1 May 2026Piper SandlerMaintainsOverweight—
26 Mar 2026Canaccord GenuityMaintainsBuy—
26 Mar 2026Wolfe ResearchUpgradePeer Perform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CORT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CORT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, Corcept Therapeutics, Inc. returned +33.1% against +16.6% for the S&P 500, dividends included.

CORT vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140Jan 26Apr 26Jul 26Oct 26CORTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CORT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+350.3%
Analysts raising
1
Analysts cutting
0
Fundamentals

Corcept Therapeutics, Inc. (CORT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
265.7×

Cheaper than 3% of US stocks

Price / sales
15.6×

Cheaper than 11% of US stocks

Price / book
18.3×

Cheaper than 5% of US stocks

EV / EBITDA
1594.8×

Cheaper than 1% of US stocks

Growth & margins
Revenue growth (YoY)
31.7%

Higher than 79% of US stocks

Earnings growth (YoY)
22.3%

Higher than 60% of US stocks

Gross margin
98.4%

Higher than 99% of US stocks

Operating margin
16.1%

Higher than 74% of US stocks

Net margin
6.6%

Higher than 64% of US stocks

Returns & dividend
Return on equity
8.2%

Higher than 59% of US stocks

Return on assets
0.5%

Higher than 46% of US stocks

Dividend yield
0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Corcept Therapeutics, Inc. (CORT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Corcept Therapeutics, Inc. has a market value of $12.9B and an enterprise value of $12.9B.

  • Revenue in the twelve months to 30 June 2026: $830.8M. The latest quarter grew 31.7% year on year.

  • Net income over the same four quarters: $55.2M, a 6.6% net margin.

  • Diluted earnings per share, trailing twelve months: $0.42.

  • Free cash flow in the twelve months to 30 June 2026: $106.9M.

  • Shares outstanding: 107.9M.

  • Trailing P/E: 265.7×; forward P/E: 27.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Corcept Therapeutics, Inc. employs 730 people — $1.1M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

CORT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CORTCorcept Therapeutics, Inc.$12.9B
79
BBIOBridgeBio Pharma, Inc.$12.8B
65
TWSTTwist Bioscience Corp.$13.5B
63
SMMTSummit Therapeutics, Inc.$13.8B
27
HALOHalozyme Therapeutics, Inc.$12.3B
97
JAZZJazz Pharmaceuticals Plc$14.8B
99
MDGLMadrigal Pharmaceuticals, Inc.$11.3B
68

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Corcept Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CORT news & analysis

4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike

Zacks Investment Research · 2 Oct 2026positive

Zacks Investment Research highlighted Corcept Therapeutics (CORT) as one of four low-beta healthcare stocks to consider amid ongoing fears of another interest-rate hike and market volatility. The article notes that low-beta healthcare names like CORT offer more defensive exposure during such uncertainty.

Why it matters — CORT watchers would care because the article positions the company's stock as a defensive, low-volatility healthcare option for investors seeking stability amid rate-hike fears and market turbulence.

Corcept Announces Planned Leadership Transition

Business Wire · 23 Sept 2026neutral

Corcept Therapeutics announced that Sean Maduck, President of the company's Endocrinology division, will retire, and Justin Gunn will succeed him, fully assuming his new responsibilities starting in October.

Why it matters — A CORT watcher would care because a leadership change in a key division could affect the company's operations and strategic direction.

CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer

Zacks Investment Research · 21 Sept 2026positive

Corcept's Lifyorli plus nab-paclitaxel received a positive CHMP opinion for the treatment of platinum-resistant ovarian cancer. An EC decision on the combination is expected in Q4 2026.

Why it matters — A positive CHMP opinion advances Lifyorli toward potential European approval, expanding Corcept's pipeline in an oncology indication.

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)

Business Wire · 18 Sept 2026positive

Corcept Therapeutics announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission approve relacorilant, combined with another treatment, for marketing authorization in the EU. The recommendation covers the drug under the proposed brand name Lifyorli.

Why it matters — CHMP's positive recommendation is a key regulatory step toward EU marketing authorization for relacorilant, potentially expanding Corcept's commercial reach beyond the US.

Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026?

Zacks Investment Research · 16 Sept 2026positive

Corcept's Korlym sales rose 6.2% in H1 2026 as demand grew, while the launch of Lifyorli provides a path to diversify the company's revenues.

Why it matters — CORT watchers would care because continued Korlym growth plus Lifyorli's launch signal potential revenue diversification beyond the company's core product.

FAQ

Frequently asked questions about CORT stock

What is the CORT stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Corcept Therapeutics, Inc. have a median 12-month price target of $164, with estimates ranging from $50 to $165. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CORT stock a buy right now?

Of the 5 analysts covering Corcept Therapeutics, Inc., 4 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Corcept Therapeutics, Inc. 79 out of 100 across roughly 4,600 US stocks as at 5 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CORT?

As at 5 Oct 2026, Corcept Therapeutics, Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (95 of 100).

Will CORT stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +37.2% from the last close, and Ticker Nerd's factor model ranks Corcept Therapeutics, Inc. 79 out of 100 as at 5 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CORT stock forecast for 2030?

No analyst covering Corcept Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CORT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $50 to $165 over the next 12 months.

How has CORT stock performed over the past year?

Corcept Therapeutics, Inc. returned +33.1% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Corcept Therapeutics, Inc. do?

Corcept Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines that modulate cortisol activity to address serious endocrine, oncologic, metabolic, and neurologic disorders.

What is the latest news on CORT?

The most recent item we track (Zacks Investment Research, 2 Oct 2026): "4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike". Zacks Investment Research highlighted Corcept Therapeutics (CORT) as one of four low-beta healthcare stocks to consider amid ongoing fears of another interest-rate hike and market volatility. The article notes that low-beta healthcare names like CORT offer more defensive exposure during such uncertainty.

Company

About Corcept Therapeutics, Inc.

Corcept Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines that modulate cortisol activity to address serious endocrine, oncologic, metabolic, and neurologic disorders. Its commercial portfolio is centered on Korlym, an oral therapy used for adults with endogenous Cushing’s syndrome and related hypercortisolism. The company also advances a pipeline of selective cortisol modulators across multiple therapeutic areas, including relacorilant for Cushing’s syndrome and certain cancers, Lifyorli for oncology, and other investigational programs in metabolic disease and amyotrophic lateral sclerosis. Corcept Therapeutics serves the specialized rare-disease and specialty-pharmaceutical markets, where its products and research are aimed at conditions with limited treatment options. The company is headquartered in Redwood City, California.

CEO Dr. Joseph K. Belanoff M.D. · 730 employees · United States · https://www.corcept.com